Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Sphingolipid signaling: a potential pathway for TNF-alpha induced preconditioning].

S Lecour1, M N Sack, L H Opie

  • 1Hatter Institute for Cardiology Research, MRC Inter-University Cape Heart Group, Chris Barnard Building, University of Cape Town Medical School, Cape Town 7925, Afrique du Sud. sandrine@capeheart.uct.ac.za

Annales De Cardiologie Et D'Angeiologie
|February 3, 2004
PubMed
Summary

Cytokines, like tumor necrosis factor-alpha (TNF alpha), may enhance heart protection during ischemia. Exploring cytokine-activated sphingolipid pathways could reveal key cardioprotective mechanisms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inter-organ communication: pathways and targets to cardioprotection and neuro-protection. A report from the 12th Hatter Cardiovascular Institute workshop.

Basic research in cardiology·2024
Same author

Remote ischaemic conditioning: defining critical criteria for success-report from the 11th Hatter Cardiovascular Workshop.

Basic research in cardiology·2022
Same author

RNase1 prevents the damaging interplay between extracellular RNA and tumour necrosis factor-α in cardiac ischaemia/reperfusion injury.

Thrombosis and haemostasis·2014
Same author

Cardiovascular prevention: lifestyle and statins--competitors or companions?

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2014
Same author

Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs.

Cardiovascular drugs and therapy·2014
Same author

Hypertension, platelets, and inflammatory responses.

Cardiovascular drugs and therapy·2014

Area of Science:

  • Cardiovascular Science
  • Molecular Biology
  • Immunology

Context:

  • Cardiac ischemia and reperfusion injury are significant clinical challenges.
  • Ischemic preconditioning is a known phenomenon that protects the heart against lethal ischemia.
  • The precise molecular mechanisms underlying ischemic preconditioning remain incompletely understood.

Purpose:

  • To explore the potential role of cytokine activation in mediating cardioprotective effects.
  • To investigate the involvement of tumor necrosis factor-alpha (TNF alpha) in the preconditioned phenotype.
  • To examine how cytokine-activated sphingolipid signaling pathways contribute to understanding preconditioning.

Summary:

  • Cytokine activation, particularly TNF alpha, is increasingly implicated in the cardioprotective effects observed during ischemic preconditioning.

Related Experiment Videos

  • Ischemic preconditioning involves a transient ischemic trigger that confers resistance to subsequent lethal ischemia.
  • Sphingolipid signaling pathways activated by cytokines offer a promising avenue for elucidating the molecular basis of this protective phenomenon.

    • Impact:

    • This research may uncover novel therapeutic targets for preventing heart damage during ischemic events.
    • Understanding cytokine-mediated pathways could lead to new strategies for enhancing cardiac resilience.
    • The findings could advance the field of cardiovascular protection by clarifying the role of innate cytoprotective programs.